Published in Cancer Cell on October 01, 2006
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood (2014) 1.61
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood (2009) 1.58
β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res (2011) 1.33
Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol (2012) 1.18
Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res (2008) 1.10
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) (2011) 1.10
Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem (2010) 1.04
β2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem (2014) 1.04
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res (2009) 0.92
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am J Blood Res (2011) 0.88
Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget (2015) 0.87
Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia (2012) 0.87
RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev (2014) 0.85
Characterization of β2-microglobulin expression in different types of breast cancer. BMC Cancer (2014) 0.84
Novel immunotherapies. Cancer J (2009) 0.82
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol (2011) 0.82
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer (2014) 0.81
Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer (2015) 0.80
MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie (2014) 0.80
Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One (2013) 0.80
Beta2-microglobulin as a potential factor for the expansion of mesenchymal stem cells. Biotechnol Lett (2009) 0.79
Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol (2014) 0.79
Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer (2010) 0.79
Decipher β2-microglobulin: gain- or loss-of-function (a mini-review). Med Sci Monit Basic Res (2013) 0.77
ATP5b and β2-microglobulin are predictive markers for the prognosis of patients with gallbladder cancer. J Mol Histol (2014) 0.77
Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC). Cancer Epidemiol Biomarkers Prev (2016) 0.76
Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. Chemotherapy (Los Angel) (2016) 0.75
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia (2016) 0.75
Upregulation of β2-microglobulin expression in progressive human oral squamous cell carcinoma. Oncol Rep (2011) 0.75
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67
The molecular classification of multiple myeloma. Blood (2006) 8.77
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science (2002) 4.45
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Multigait soft robot. Proc Natl Acad Sci U S A (2011) 3.57
Mammalian defensins in immunity: more than just microbicidal. Trends Immunol (2002) 3.52
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol (2004) 2.81
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol (2008) 2.64
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 2.62
Microsurgical keyhole approach for middle fossa arachnoid cyst fenestration. Neurosurgery (2003) 2.58
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Post-traumatic endophthalmitis. Ophthalmology (2004) 2.53
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the "heat sink" effect. AJR Am J Roentgenol (2002) 2.31
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis (2008) 2.26
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res (2008) 2.13
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis (2010) 2.10
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol (2013) 2.01
Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res (2004) 1.98
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Familial myeloma. N Engl J Med (2008) 1.96
The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. Nat Immunol (2011) 1.96
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood (2012) 1.93
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 1.93
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med (2004) 1.85
Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol (2013) 1.84
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol (2010) 1.84
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer (2008) 1.82
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res (2003) 1.81
Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci U S A (2007) 1.80
Th9 cells promote antitumor immune responses in vivo. J Clin Invest (2012) 1.80
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A (2010) 1.78
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol (2002) 1.74
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica (2010) 1.73
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci U S A (2004) 1.72
Life-cycle greenhouse gas emissions of shale gas, natural gas, coal, and petroleum. Environ Sci Technol (2011) 1.70
Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis (2011) 1.70
Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood (2002) 1.69
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood (2002) 1.65
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol (2006) 1.64
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet (2012) 1.64
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med (2005) 1.63
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood (2009) 1.61
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood (2014) 1.59
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica (2006) 1.58
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood (2009) 1.58